# OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

> **NCT02054156** · PHASE3 · COMPLETED · sponsor: **Bonnie Ramsey** · enrollment: 221 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** azithromycin
- **DRUG:** placebo
- **DRUG:** Tobramycin solution for inhalation

## Key facts

- **NCT ID:** NCT02054156
- **Lead sponsor:** Bonnie Ramsey
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-08-23
- **Final completion:** 2018-08-23
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2019-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054156, "OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02054156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*